3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Breast Neoplasms
9
Endometrial Neoplasms
4
Carcinoma, Renal Cell
4
Neuroendocrine Tumors
3
Tuberous Sclerosis
2
Recurrence
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Solid Tumor
1
Seizures
1
Sarcoma
1
Primary Non-metastatic Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Hyperplasia
1
Clear-cell metastatic renal cell carcinoma
1
Breast Neoplasms, Male
1
Angiomyolipoma
1
Advanced Solid Tumors
1
Advanced Cancer
1
Interventions
lutetium Lu 177 dotatate
2
pasireotide
1
copper dotatate CU-64
1
amino-acid, glucose, and electrolyte solution
1
abemaciclib
1
Temozolomide
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Octreotide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Everolimus
1
E-7386
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
Everolimus
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled